Frazier Management’s Regenxbio RGNX Stock Holding History

Frazier Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-235,809	Closed	-$7.71M	–	23
2021 Q4	$7.71M	Hold	235,809	–	–	0.59%	34
2021 Q3	$9.88M	Sell	235,809 -116,145	-33%	-$4.18M	0.79%	27
2021 Q2	$13.7M	Hold	351,954	–	–	1.26%	19
2021 Q1	$12M	Buy	351,954 +10,000	+3%	+$426K	0.96%	20
2020 Q4	$15.5M	Buy	341,954 +167,754	+96%	+$5.86M	1.19%	19
2020 Q3	$4.79M	Buy	+174,200	New	+$5.68M	0.43%	21

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frazier Management's RGNX Position: Q1 2022 in Review

Frazier Management sold out of Regenxbio (RGNX) in Q1 2022, closing a stake of 235,809 shares — an estimated $7.71M sold.

Frazier Management first reported a position in RGNX in Q3 2020 and held it in 6 quarters. The position peaked at $15.5M in Q4 2020. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2022.

Frazier Management reported no remaining Regenxbio position as of Q1 2022 after selling out during the quarter.
Frazier Management sold 235,809 Regenxbio shares in Q1 2022, an estimated $7.71M.
Frazier Management first reported a position in Regenxbio in Q3 2020 and held it in 6 quarters.
Frazier Management's Regenxbio position peaked at $15.5M in Q4 2020.
188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.